Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.06
NYSE:TEVA's Cash-to-Debt is ranked lower than
95% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. NYSE:TEVA: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:TEVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.22 Max: 1.03
Current: 0.06
0.02
1.03
Equity-to-Asset 0.27
NYSE:TEVA's Equity-to-Asset is ranked lower than
89% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NYSE:TEVA: 0.27 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:TEVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.48 Max: 0.6
Current: 0.27
0.25
0.6
Debt-to-Equity 1.69
NYSE:TEVA's Debt-to-Equity is ranked lower than
94% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. NYSE:TEVA: 1.69 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:TEVA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.27  Med: 0.6 Max: 1.87
Current: 1.69
0.27
1.87
Debt-to-EBITDA -2.98
NYSE:TEVA's Debt-to-EBITDA is ranked lower than
99.99% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. NYSE:TEVA: -2.98 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:TEVA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.98  Med: 2.97 Max: 12.37
Current: -2.98
-2.98
12.37
Interest Coverage 3.89
NYSE:TEVA's Interest Coverage is ranked lower than
84% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. NYSE:TEVA: 3.89 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:TEVA' s Interest Coverage Range Over the Past 10 Years
Min: 3.89  Med: 13.79 Max: 21.19
Current: 3.89
3.89
21.19
Piotroski F-Score: 4
Altman Z-Score: -0.01
Beneish M-Score: -2.65
WACC vs ROIC
4.09%
5.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 17.49
NYSE:TEVA's Operating Margin % is ranked higher than
78% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. NYSE:TEVA: 17.49 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:TEVA' s Operating Margin % Range Over the Past 10 Years
Min: 11.45  Med: 21.5 Max: 26.56
Current: 17.49
11.45
26.56
Net Margin % -47.98
NYSE:TEVA's Net Margin % is ranked lower than
82% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. NYSE:TEVA: -47.98 )
Ranked among companies with meaningful Net Margin % only.
NYSE:TEVA' s Net Margin % Range Over the Past 10 Years
Min: -72.66  Med: 8.87 Max: 20.66
Current: -47.98
-72.66
20.66
ROE % -46.37
NYSE:TEVA's ROE % is ranked lower than
83% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. NYSE:TEVA: -46.37 )
Ranked among companies with meaningful ROE % only.
NYSE:TEVA' s ROE % Range Over the Past 10 Years
Min: -65.19  Med: 7.33 Max: 16.18
Current: -46.37
-65.19
16.18
ROA % -13.18
NYSE:TEVA's ROA % is ranked lower than
74% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. NYSE:TEVA: -13.18 )
Ranked among companies with meaningful ROA % only.
NYSE:TEVA' s ROA % Range Over the Past 10 Years
Min: -19.88  Med: 3.53 Max: 9.34
Current: -13.18
-19.88
9.34
ROC (Joel Greenblatt) % -139.95
NYSE:TEVA's ROC (Joel Greenblatt) % is ranked lower than
80% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. NYSE:TEVA: -139.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:TEVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -206.93  Med: 27 Max: 49.49
Current: -139.95
-206.93
49.49
3-Year Revenue Growth Rate -2.30
NYSE:TEVA's 3-Year Revenue Growth Rate is ranked lower than
75% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. NYSE:TEVA: -2.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:TEVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.3  Med: 14.8 Max: 23.8
Current: -2.3
-2.3
23.8
GuruFocus has detected 3 Warning Signs with Teva Pharmaceutical Industries Ltd NYSE:TEVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:TEVA's 30-Y Financials

Financials (Next Earnings Date: 2018-11-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

TEVA Guru Trades in Q3 2017

David Abrams 21,623,886 sh (New)
Steven Cohen 125,000 sh (New)
Vanguard Health Care Fund 27,180,276 sh (+70.25%)
Caxton Associates 13,300 sh (+2.31%)
Bernard Horn 199,100 sh (unchged)
First Eagle Investment 200 sh (unchged)
Ronald Muhlenkamp 13,000 sh (unchged)
Ray Dalio 27,700 sh (unchged)
George Soros 1,190,000 sh (unchged)
Francis Chou 505,000 sh (unchged)
Richard Snow Sold Out
Julian Robertson Sold Out
NWQ Managers 953,454 sh (-1.43%)
David Dreman 42,048 sh (-5.38%)
John Paulson 2,450,000 sh (-63.67%)
Barrow, Hanley, Mewhinney & Strauss 4,716,868 sh (-84.26%)
Michael Price 54,875 sh (-92.38%)
Ronald Muhlenkamp 700 sh (-99.34%)
» More
Q4 2017

TEVA Guru Trades in Q4 2017

Francisco García Paramés 696,509 sh (New)
Pioneer Investments 59,042 sh (New)
Jana Partners 3,582,713 sh (New)
Warren Buffett 18,875,721 sh (New)
Steven Cohen 327,650 sh (+162.12%)
Bernard Horn 414,400 sh (+108.14%)
Michael Price 104,875 sh (+91.12%)
NWQ Managers 1,204,186 sh (+26.30%)
Vanguard Health Care Fund 31,351,001 sh (+15.34%)
First Eagle Investment 200 sh (unchged)
Ray Dalio 27,700 sh (unchged)
Ronald Muhlenkamp 700 sh (unchged)
Ronald Muhlenkamp 13,000 sh (unchged)
George Soros 1,190,000 sh (unchged)
Caxton Associates Sold Out
John Paulson Sold Out
David Abrams 19,743,123 sh (-8.70%)
Barrow, Hanley, Mewhinney & Strauss 2,878,493 sh (-38.97%)
Francis Chou 15,000 sh (-97.03%)
David Dreman 161 sh (-99.62%)
» More
Q1 2018

TEVA Guru Trades in Q1 2018

Jim Simons 900,963 sh (New)
Caxton Associates 54,000 sh (New)
Warren Buffett 40,539,710 sh (+114.77%)
Pioneer Investments 71,200 sh (+20.59%)
David Dreman 161 sh (unchged)
Francis Chou 15,000 sh (unchged)
David Abrams 19,743,123 sh (unchged)
Michael Price 104,875 sh (unchged)
George Soros 250,000 sh (unchged)
Bernard Horn 414,400 sh (unchged)
Ronald Muhlenkamp Sold Out
Steven Cohen Sold Out
First Eagle Investment Sold Out
Barrow, Hanley, Mewhinney & Strauss 2,837,834 sh (-1.41%)
Jana Partners 3,476,348 sh (-2.97%)
Vanguard Health Care Fund 27,983,701 sh (-10.74%)
Francisco García Paramés 598,001 sh (-14.14%)
Ray Dalio 21,200 sh (-23.47%)
NWQ Managers 178,402 sh (-85.18%)
» More
Q2 2018

TEVA Guru Trades in Q2 2018

Ken Fisher 10,625 sh (New)
Steven Cohen 3,731,314 sh (New)
Jeremy Grantham 36,900 sh (New)
George Soros 160,000 sh (New)
Jim Simons 4,036,863 sh (+348.06%)
Warren Buffett 43,249,295 sh (+6.68%)
Pioneer Investments 72,497 sh (+1.82%)
David Abrams 19,743,123 sh (unchged)
Michael Price 104,875 sh (unchged)
Francis Chou 15,000 sh (unchged)
Ray Dalio 21,200 sh (unchged)
George Soros 250,000 sh (unchged)
Bernard Horn 414,400 sh (unchged)
NWQ Managers Sold Out
Caxton Associates Sold Out
Barrow, Hanley, Mewhinney & Strauss 2,831,134 sh (-0.24%)
Francisco García Paramés 564,802 sh (-5.55%)
Jana Partners 2,935,807 sh (-15.55%)
Vanguard Health Care Fund 19,274,601 sh (-31.12%)
» More
» Details

Insider Trades

Latest Guru Trades with TEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Warren Buffett 2018-06-30 Add 6.68%0.03%$16.77 - $24.71 $ 22.269%43,249,295
Vanguard Health Care Fund 2018-06-30 Reduce -31.12%0.33%$16.77 - $24.71 $ 22.269%19,274,601
Barrow, Hanley, Mewhinney & Strauss 2018-06-30 Reduce -0.24%$16.77 - $24.71 $ 22.269%2,831,134
George Soros 2018-06-30 New Buy0.07%$16.77 - $24.71 $ 22.269%160,000
Ken Fisher 2018-06-30 New Buy$16.77 - $24.71 $ 22.269%10,625
NWQ Managers 2018-06-30 Sold Out 0.05%$16.77 - $24.71 $ 22.269%0
Warren Buffett 2018-03-31 Add 114.77%0.2%$16.68 - $22.07 $ 22.2614%40,539,710
Vanguard Health Care Fund 2018-03-31 Reduce -10.74%0.14%$16.68 - $22.07 $ 22.2614%27,983,701
Barrow, Hanley, Mewhinney & Strauss 2018-03-31 Reduce -1.41%$16.68 - $22.07 $ 22.2614%2,837,834
NWQ Managers 2018-03-31 Reduce -85.18%0.28%$16.68 - $22.07 $ 22.2614%178,402
Ronald Muhlenkamp 2018-03-31 Sold Out $16.68 - $22.07 $ 22.2614%0
First Eagle Investment 2018-03-31 Sold Out $16.68 - $22.07 $ 22.2614%0
Vanguard Health Care Fund 2017-12-31 Add 15.34%0.17%$11.23 - $19.1 $ 22.2648%31,351,001
Warren Buffett 2017-12-31 New Buy0.19%$11.23 - $19.1 $ 22.2648%18,875,721
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -38.97%0.05%$11.23 - $19.1 $ 22.2648%2,878,493
NWQ Managers 2017-12-31 Add 26.30%0.07%$11.23 - $19.1 $ 22.2648%1,204,186
Michael Price 2017-12-31 Add 91.12%0.12%$11.23 - $19.1 $ 22.2648%104,875
David Dreman 2017-12-31 Reduce -99.62%0.41%$11.23 - $19.1 $ 22.2648%161
John Paulson 2017-12-31 Sold Out 0.78%$11.23 - $19.1 $ 22.2648%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF.PFD415.004.287 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:SHSE:600518, TSE:4507, NSE:SUNPHARMA, SZSE:000538, TSE:4523, SHSE:600196, NAS:MYL, XPAR:IPN, OCSE:LUN, NYSE:PRGO, TSE:4508, SZSE:000963, XSWX:VIFN, SZSE:300122, JSE:APN, SHSE:600332, HKSE:03320, SHSE:600085, TSE:4581, SHSE:600535 » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVJF.USA,
Headquarter Location:Israel
Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces and markets generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines.

Headquartered in Israel, Teva Pharmaceutical is the world's largest generic pharmaceutical manufacturer. The company also develops and sells branded pharmaceuticals in central nervous system, oncology, respiratory, and women's health categories. After acquiring Allergan's generics business, Teva's generic sales should be over 60% of total revenue, with branded drug and international over-the-counter revenue making up the balance of sales. Copaxone makes up about half of Teva's branded drug segment, with about $4 billion in sales for 2015.

Guru Investment Theses on Teva Pharmaceutical Industries Ltd

Bernard Horn Comments on Teva Pharmaceuticals - Jul 23, 2018

Teva Pharmaceutical (NYSE:TEVA), the Israeli-based generic drug company, rebounded from prior lows as it continued its restructuring and reduced debt. The company reaffirmed the long-term safety of its blockbuster branded drug, Copaxone, and expects its new migraine therapy to undergo FDA review in 2018.



From Bernard Horn (Trades, Portfolio)'s Polaris Global Value Fund 2nd quarter 2018 shareholder letter.



Check out Bernard Horn latest stock trades

Bernard Horn Comments on Teva Pharmaceutical - Apr 16, 2018

Teva Pharmaceutical (NYSE:TEVA) continued to face headwinds, with sluggish generic product introductions and pricing pressures. With a new CEO at the helm, Teva launched a comprehensive restructuring plan to shore up its balance sheet. The company enacted layoffs and plant closures, optimized its generics portfolio and reviewed of its R&D and drug pipeline. Consistent with this agenda, Teva announced the termination of its CGRP migraine drug discovery and development pact with Sosei. The company also renegotiated some of its debt at much higher interest rates than previous. Neither of these actions was well received by the market.

From Bernard Horn (Trades, Portfolio)'s first quarter 2018 shareholder letter.

Check out Bernard Horn latest stock trades

Bernard Horn Comments on Teva Pharmaceutical - Oct 18, 2017

Teva Pharmaceutical (NYSE:TEVA), the Israeli drug company, dropped materially during the quarter. The company faced a perfect storm of industry pressures and self-inflicted missteps. Pricing pressure in the U.S. generics market was worse than normal. The resultant lower cash flow, and a high debt load from the Allergan acquisition, forced the company to cut its dividend and warn that debt covenants may be violated. Management planned asset sales to help alleviate cash requirements. Generic drug competition also impacted Allergan, as the stock declined nearly 15% on concerns of a 2018 generic alternative to Allergan’s flagship Alzheimer’s drug, Namenda. However, Allergan’s current drug portfolio remains resilient, led by advances in Botox and the introduction of Namzaric. Company management also signaled its intention to add new medicines and expand via acquisitions.

From Bernard Horn (Trades, Portfolio)'s third quarter 2017 shareholder commentary.

Check out Bernard Horn latest stock trades

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

Teva, NACHC and Direct Relief Provide Important Insights on Prescription Medicine Access for Underserved Patients at the AAM Conference
Bernard Horn’s Top 3 Buys in 2nd Quarter Top buys include two consumer cyclical companies. Health care stocks contribute to portfolio return
Bernard Horn (Trades, Portfolio), manager of Polaris Capital Management, disclosed on Aug. 31 that the firm established three new positions during the second quarter: Publicis Groupe SA (XPAR:PUB), Shinhan Financial Group Co. Ltd. (XKRX:055550) and Inchcape PLC (LSE:INCH). Read more...
Teva’s Recovery Is Just Beginning Despite intense competition, Teva's future does seem bright with a massive corporate restructuring underway, cost cutting and a promising pipeline
Teva Pharmaceuticals (TEVA) is not a company I would typically consider investing in. It was a mere three years ago that it hit an all-time high of $70, only to sink to $11 in November 2017. The decline in stock price correlated with the spike in debt and to many, the glory days of Teva had officially come to an end. Read more...
Recent Analysis Shows Magic Software Enterprises, Resonant, Landec, BlackBerry, Teva Pharmaceutical Industries, and Herbalife LTD Market Influences — Renewed Outlook, Key Drivers of Growth
US Stock Market Opens Lower on Thursday Teva's stock drops more than 4%
U.S. stock markets were trading lower Thursday morning despite the season of corporate earnings results.  Read more...
Bernard Horn Comments on Teva Pharmaceuticals Guru stock highlight
Teva Pharmaceutical (NYSE:TEVA), the Israeli-based generic drug company, rebounded from prior lows as it continued its restructuring and reduced debt. The company reaffirmed the long-term safety of its blockbuster branded drug, Copaxone, and expects its new migraine therapy to undergo FDA review in 2018.
Read more...
Analysis: Positioning to Benefit within Teva Pharmaceutical Industries, Resonant, United Community Financial, Enbridge, Shopify, and Dell Technologies — Research Highlights Growth, Revenue, and Consolidated Results
2 Stocks to Watch on Thursday Teva Pharmaceutical and Kraft Heinz move on quarterly financial results
In Thursday trading, shares of Teva Pharmaceutical (NYSE:TEVA) advanced after reporting first-quarter earnings per share of 94 cents on revenue of $5.07 billion, down10.3% year-over-year. The company managed to beat earnings estimates by 28 cents and revenue estimations by $270 million. Read more...
Bernard Horn Comments on Teva Pharmaceutical Guru stock highlight
Teva Pharmaceutical (NYSE:TEVA) continued to face headwinds, with sluggish generic product introductions and pricing pressures. With a new CEO at the helm, Teva launched a comprehensive restructuring plan to shore up its balance sheet. The company enacted layoffs and plant closures, optimized its generics portfolio and reviewed of its R&D and drug pipeline. Consistent with this agenda, Teva announced the termination of its CGRP migraine drug discovery and development pact with Sosei. The company also renegotiated some of its debt at much higher interest rates than previous. Neither of these actions was well received by the market. Read more...
Should You Follow Buffett Into Teva Pharmaceutical? The company does not fit Warren Buffett's typical mold
Buying companies that have fallen out of favor with the rest of market has always been a skill of Warren Buffett (Trades, Portfolio) and his team at Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B). Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 7.63
TEVA's Forward PE Ratio is ranked higher than
94% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. TEVA: 7.63 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.61
TEVA's PB Ratio is ranked higher than
72% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. TEVA: 1.61 )
Ranked among companies with meaningful PB Ratio only.
TEVA' s PB Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.86 Max: 2.91
Current: 1.61
0.4
2.91
PS Ratio 1.06
TEVA's PS Ratio is ranked higher than
82% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TEVA: 1.06 )
Ranked among companies with meaningful PS Ratio only.
TEVA' s PS Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.34 Max: 4.33
Current: 1.06
0.49
4.33
Price-to-Free-Cash-Flow 5.27
TEVA's Price-to-Free-Cash-Flow is ranked higher than
96% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. TEVA: 5.27 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TEVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.81  Med: 12.13 Max: 32.03
Current: 5.27
3.81
32.03
Price-to-Operating-Cash-Flow 4.94
TEVA's Price-to-Operating-Cash-Flow is ranked higher than
95% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. TEVA: 4.94 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TEVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.53  Med: 9.59 Max: 22.47
Current: 4.94
3.53
22.47
EV-to-EBIT -5.04
TEVA's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. TEVA: -5.04 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.7  Med: 17.6 Max: 87.1
Current: -5.04
-14.7
87.1
EV-to-EBITDA -5.54
TEVA's EV-to-EBITDA is ranked lower than
99.99% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. TEVA: -5.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.6  Med: 12.5 Max: 47.1
Current: -5.54
-18.6
47.1
EV-to-Revenue 2.68
TEVA's EV-to-Revenue is ranked higher than
58% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. TEVA: 2.68 )
Ranked among companies with meaningful EV-to-Revenue only.
TEVA' s EV-to-Revenue Range Over the Past 10 Years
Min: 2  Med: 3 Max: 4.6
Current: 2.68
2
4.6
Shiller PE Ratio 53.21
TEVA's Shiller PE Ratio is ranked lower than
72% of the 252 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.75 vs. TEVA: 53.21 )
Ranked among companies with meaningful Shiller PE Ratio only.
TEVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 6.91  Med: 25.68 Max: 58
Current: 53.21
6.91
58
Current Ratio 1.03
TEVA's Current Ratio is ranked lower than
86% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. TEVA: 1.03 )
Ranked among companies with meaningful Current Ratio only.
TEVA' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.56 Max: 2.95
Current: 1.03
0.86
2.95
Quick Ratio 0.69
TEVA's Quick Ratio is ranked lower than
86% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. TEVA: 0.69 )
Ranked among companies with meaningful Quick Ratio only.
TEVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.58  Med: 1.01 Max: 2.19
Current: 0.69
0.58
2.19
Days Inventory 163.65
TEVA's Days Inventory is ranked lower than
70% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. TEVA: 163.65 )
Ranked among companies with meaningful Days Inventory only.
TEVA' s Days Inventory Range Over the Past 10 Years
Min: 155.95  Med: 186.4 Max: 208.14
Current: 163.65
155.95
208.14
Days Sales Outstanding 106.18
TEVA's Days Sales Outstanding is ranked lower than
69% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. TEVA: 106.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 120.04 Max: 153.21
Current: 106.18
95.91
153.21
Days Payable 57.76
TEVA's Days Payable is ranked lower than
64% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. TEVA: 57.76 )
Ranked among companies with meaningful Days Payable only.
TEVA' s Days Payable Range Over the Past 10 Years
Min: 57.76  Med: 78.39 Max: 84.39
Current: 57.76
57.76
84.39

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.39
TEVA's Dividend Yield % is ranked higher than
90% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. TEVA: 0.39 )
Ranked among companies with meaningful Dividend Yield % only.
TEVA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.39  Med: 2.25 Max: 9.69
Current: 0.39
0.39
9.69
3-Year Dividend Growth Rate -14.70
TEVA's 3-Year Dividend Growth Rate is ranked lower than
80% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. TEVA: -14.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TEVA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -14.7  Med: 23.6 Max: 80.9
Current: -14.7
-14.7
80.9
5-Year Yield-on-Cost % 0.35
TEVA's 5-Year Yield-on-Cost % is ranked higher than
74% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. TEVA: 0.35 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TEVA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.35  Med: 2.01 Max: 8.67
Current: 0.35
0.35
8.67
3-Year Average Share Buyback Ratio -6.10
TEVA's 3-Year Average Share Buyback Ratio is ranked lower than
52% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. TEVA: -6.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.6  Med: -3.6 Max: 4.6
Current: -6.1
-12.6
4.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.45
TEVA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
97% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. TEVA: 0.45 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TEVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.31  Med: 1.52 Max: 11.3
Current: 0.45
0.31
11.3
Price-to-Median-PS-Value 0.46
TEVA's Price-to-Median-PS-Value is ranked higher than
87% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. TEVA: 0.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TEVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.17 Max: 2.49
Current: 0.46
0.33
2.49
Earnings Yield (Greenblatt) % -19.84
TEVA's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. TEVA: -19.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TEVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -33.6  Med: 4.8 Max: 9.2
Current: -19.84
-33.6
9.2
Forward Rate of Return (Yacktman) % 10.71
TEVA's Forward Rate of Return (Yacktman) % is ranked higher than
52% of the 421 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.96 vs. TEVA: 10.71 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TEVA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -82334.6  Med: 14.9 Max: 1429742.6
Current: 10.71
-82334.6
1429742.6

More Statistics

Revenue (TTM) (Mil) $20,835.00
EPS (TTM) $ -10.10
Beta0.97
Volatility47.51%
52-Week Range $10.85 - 25.96
Shares Outstanding (Mil)1,018.28 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 18,853 18,020 17,950 18,671
EBIT (Mil $) 3,412 3,818 4,649
EBITDA (Mil $) 4,994 5,088 5,128 5,346
EPS ($) 1.09 1.84 2.47 3.12
EPS without NRI ($) 1.09 1.84 2.47 3.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-1.01%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}